JADE vs. RTW, SURE, APQ, PRIM, TPOU, VOX, KZG, BAF, MAFL, and INV
Should you be buying Jade Road Investments stock or one of its competitors? The main competitors of Jade Road Investments include RTW Biotech Opportunities (RTW), Sure Ventures (SURE), APQ Global (APQ), Primorus Investments (PRIM), Third Point Investors (TPOU), Vox Valor Capital (VOX), Kazera Global (KZG), British & American Investment Trust (BAF), Mineral & Financial Investments (MAFL), and Investment (INV). These companies are all part of the "asset management" industry.
Jade Road Investments (LON:JADE) and RTW Biotech Opportunities (LON:RTW) are both small-cap financial services companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.
Jade Road Investments has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, RTW Biotech Opportunities has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.
In the previous week, RTW Biotech Opportunities had 2 more articles in the media than Jade Road Investments. MarketBeat recorded 2 mentions for RTW Biotech Opportunities and 0 mentions for Jade Road Investments. RTW Biotech Opportunities' average media sentiment score of 0.28 beat Jade Road Investments' score of 0.00 indicating that RTW Biotech Opportunities is being referred to more favorably in the news media.
RTW Biotech Opportunities has higher revenue and earnings than Jade Road Investments. Jade Road Investments is trading at a lower price-to-earnings ratio than RTW Biotech Opportunities, indicating that it is currently the more affordable of the two stocks.
56.1% of Jade Road Investments shares are held by institutional investors. Comparatively, 11.1% of RTW Biotech Opportunities shares are held by institutional investors. 23.2% of Jade Road Investments shares are held by insiders. Comparatively, 12.3% of RTW Biotech Opportunities shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
RTW Biotech Opportunities has a net margin of 1,994.76% compared to Jade Road Investments' net margin of 0.00%. RTW Biotech Opportunities' return on equity of 21.42% beat Jade Road Investments' return on equity.
RTW Biotech Opportunities received 1 more outperform votes than Jade Road Investments when rated by MarketBeat users.
Summary
RTW Biotech Opportunities beats Jade Road Investments on 11 of the 13 factors compared between the two stocks.
Get Jade Road Investments News Delivered to You Automatically
Sign up to receive the latest news and ratings for JADE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JADE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jade Road Investments Competitors List
Related Companies and Tools
